Abstract
Mutations of KRAS are found in a variety of human malignancies, including in pancreatic cancer, colorectal cancer, and non-small cell lung cancer at high frequency. To date, no effective treatments that target mutant variants of KRAS have been introduced into clinical practice. In recent years, a number of studies have shown that the oncogene KRAS plays a critical role in controlling cancer metabolism by orchestrating multiple metabolic changes. One of the metabolic hallmarks of malignant tumor cells is their dependency on aerobic glycolysis, known as the Warburg effect. The role of KRAS signaling in the regulation of aerobic glycolysis has been reported in several types of cancer. KRAS-driven cancers are characterized by altered metabolic pathways involving enhanced nutrients uptake, enhanced glycolysis, enhanced glutaminolysis, and elevated synthesis of fatty acids and nucleotides. However, Just how mutated KRAS can coordinate the metabolic shift to promote tumor growth and whether specific metabolic pathways are essential for the tumorigenesis of KRAS-driven cancers are questions which remain to be answered. In this context, the aim of this review is to summarize current data on KRAS-related metabolic alterations in cancer cells. Given that cancer cells rely on changes in metabolism to support their growth and survival, the targeting of metabolic processes may be a potential strategy for treating KRAS-driven cancers.
Similar content being viewed by others
Abbreviations
- ACS:
-
Acyl-CoA synthetase
- ASNS:
-
Asparagine synthetase
- BCAA:
-
Branched-chain amino acid
- CMS:
-
Consensus molecular subtype
- CRC:
-
Colorectal cancer
- EGFR:
-
Epidermal growth factor receptor
- FA:
-
Fatty acid
- FASN:
-
Fatty acid synthase
- FDG:
-
Fluorodeoxyglucose
- FGFR:
-
Fibroblast growth factor receptor
- GLS:
-
Glutaminase
- GLUD1:
-
Glutamate dehydrogenase 1
- GLUT1:
-
Glucose transporter-1
- GOT:
-
Glutamate–oxaloacetate transaminase
- HBP:
-
Hexosamine biosynthesis pathway
- HK:
-
Hexokinase
- MDH1:
-
Malate dehydrogenase 1
- mTOR:
-
Mammalian target of rapamycin
- NSCLC:
-
Non-small cell lung cancer
- PDCA:
-
Pancreatic ductal cell carcinoma
- PET:
-
Positron emission tomography
- PKM2:
-
Pyruvate kinase M2
- PPP:
-
Pentose phosphate pathway
- ROS:
-
Reactive oxygen species
- TCA:
-
Tricarboxylic acid
- UPR:
-
Unfolded protein response
References
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033
Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11:325–337
Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95
Galluzzi L, Kepp O, Vander Heiden MG et al (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12:829–846
Warburg O (1956) Injuring of respiration the origin of cancer cells. Science 123:309–314
Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9:517–531
Gysin S, Salt M, Young A et al (2011) Therapeutic strategies for targeting ras proteins. Genes Cancer 2:359–372
Eagle H (1955) Nutrition needs of mammalian cells in tissue culture. Science 122:501–514
Kovacević Z, Morris HP (1972) The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res 32:326–333
Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35:427–433
Bryant KL, Mancias JD, Kimmelman AC et al (2014) KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 39:91–100
Cohen R, Neuzillet C, Tijeras-Raballand A et al (2015) Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget 6:16832–16847
Kimmelman AC (2015) Metabolic dependencies in RAS-driven cancers. Clin Cancer Res 21:1828–1834
White E (2013) Exploiting the bad eating habits of Ras-driven cancers. Genes Dev 27:2065–2071
Rabinowitz JD, White E (2010) Autophagy and metabolism. Science 330:1344–1348
Commisso C, Davidson SM, Soydaner-Azeloglu RG et al (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497:633–637
Vincent A, Herman J, Schulick R et al (2011) Pancreatic cancer. Lancet 378:607–620
Ying H, Kimmelman AC, Lyssiotis CA et al (2012) Oncogenic KRAS maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149:656–670
Csibi A, Lee G, Yoon SO et al (2014) The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol 24:2274–2280
DeBerardinis RJ, Cheng T (2010) Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:313–324
Bhutia YD, Babu E, Ramachandran S et al (2015) Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. Cancer Res 75:1782–1788
Son J, Lyssiotis CA, Ying H et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101–105
Wang YP, Zhou W, Wang J et al (2016) Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol Cell 64:673–687
Mayers JR, Wu C, Clish CB et al (2014) Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 20:1193–1198
Mayers JR, Torrence ME, Danai LV et al (2016) Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353:1161–1165
Yang S, Wang X, Contino G et al (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25:717–729
Guo JY, Chen HY, Mathew R et al (2011) Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 25:460–470
Eng CH, Wang Z, Tkach D et al (2016) Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci USA 113:182–187
White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12:401–410
Rosenfeld MR, Ye X, Supko JG et al (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359–1368
Mahalingam D, Mita M, Sarantopoulos J et al (2014) Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10:1403–1414
Wolpin BM, Rubinson DA, Wang X et al (2014) Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 19:637–638
Palm W, Park Y, Wright K et al (2015) The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell 162:259–270
Kamphorst JJ, Cross JR, Fan J et al (2013) Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci USA 110:8882–8887
Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799
Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancers. N Engl J Med 359:1757–1765
Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379
Guinney J, Dienstmann R, Wang X et al (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350–1356
Yun J, Rago C, Cheong I et al (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325:1555–1559
Jadvar H, Alavi A, Gambhir SS (2009) 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50:1820–1827
Kawada K, Nakamoto Y, Kawada M et al (2012) Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res 18:1696–1703
Kawada K, Toda K, Nakamoto Y et al (2015) Relationship between 18F-FDG PET/CT scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med 56:1322–1327
Kawada K, Iwamoto M, Sakai Y (2016) Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol 8:880–886
Chen SW, Chiang HC, Chen WT et al (2014) Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med 39:685–689
Miles KA, Ganeshan B, Rodriguez-Justo M et al (2014) Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med 55:386–391
Lee JH, Kang J, Baik SH et al (2016) Relationship between 18F-Fluorodeoxyglucose uptake and V-Ki-Ras2 kirsten rat sarcoma viral oncogene homolog mutation in colorectal cancer patients: variability depending on c-reactive protein level. Medicine 95:e2236
Caicedo C, Garcia-Velloso MJ, Lozano MD et al (2014) Role of [1∙F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 41:2058–2065
Iwamoto M, Kawada K, Nakamoto Y et al (2014) Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med 55:2038–2044
Yun J, Mullarky E, Lu C et al (2015) Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350:1391–1396
Aguilera O, Muñoz-Sagastibelza M, Torrejón B et al (2016) Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. Oncotarget 7:47954–47965
Toda K, Kawada K, Iwamoto M et al (2016) Metabolic alterations caused by KRAS mutations in colorectal cancer contribute to cell adaptation to glutamine depletion by upregulation of asparagine synthetase. Neoplasia 18:654–665
Zhang J, Fan J, Venneti S et al (2014) Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell 56:205–218
Hettmer S, Schinzel AC, Tchessalova D et al (2015) Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. Elife 4:e09436. doi:10.7554/eLife.09436
Ye J, Kumanova M, Hart LS et al (2010) The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 29:2082–2096
Balasubramanian MN, Butterworth EA, Kilberg MS (2013) Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab 304:789–799
Dufour E, Gay F, Aguera K et al (2012) Pancreatic tumor sensitivity to plasma l-asparagine starvation. Pancreas 41:940–948
Richards NG, Kilberg MS (2006) Asparagine synthetase chemotherapy. Annu Rev Biochem 75:629–654
Ikeuchi H, Ahn YM, Otokawa T et al (2012) A sulfoximine-based inhibitor of human asparagine synthetase kills l-asparaginase-resistant leukemia cells. Bioorg Med Chem 20:5915–5927
Kral AS, Xu S, Graeber TG et al (2016) Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun 7:11457
Weinberg F, Hamanaka R, Wheaton WW et al (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107:8788–8793
Wong CC, Qian Y, Li X et al (2016) SLC25A22 promotes proliferation and survival of colorectal cancer cells with KRAS mutations and xenograft tumor progression in mice via intracellular synthesis of aspartate. Gastroenterology 151(945–960):e6
Miyo M, Konno M, Nishida N et al (2016) Metabolic adaptation to nutritional stress in human colorectal cancer. Sci Rep 6:38415
Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254–266
Bhutia YD, Ganapathy V (2016) Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta 1863:2531–2539
Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380
Manchado E, Weissmueller S, Morris JP 4th (2016) A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534:647–651
Patra KC, Wang Q, Bhaskar PT et al (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24:213–228
Jain M, Nilsson R, Sharma S et al (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336:1040–1044
Kim D, Fiske BP, Birsoy K et al (2015) SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature 520:363–367
Guo JY, Karsli-Uzunbas G, Mathew R et al (2013) Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 27:1447–1461
Padanad MS, Konstantinidou G, Venkateswaran N (2016) Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis. Cell Rep 16:1614–1628
Gouw AM, Eberlin LS, Margulis K (2017) Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci USA 114:4300–4305
Davidson SM, Papagiannakopoulos T, Olenchzock BA et al (2016) Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab 23:517–528
Zhou B, Der CJ, Cox AD (2016) The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol 58:60–69
Ratnikov BI, Scott DA, Osterman AL (2017) Metabolic rewiring in melanoma. Oncogene 36:147–157
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no potential conflicts of interest to be disclosed.
About this article
Cite this article
Kawada, K., Toda, K. & Sakai, Y. Targeting metabolic reprogramming in KRAS-driven cancers. Int J Clin Oncol 22, 651–659 (2017). https://doi.org/10.1007/s10147-017-1156-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-017-1156-4